Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18f-lbt-999
- Development stage
- Phase 3
- Lead developer
- Inserm
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
18F-LBT-999 is a fluorine-18 labeled radiopharmaceutical developed by the Institut National de la Santé et de la Recherche Médicale (INSERM) for use in positron emission tomography (PET) imaging. It is a tropane derivative that functions as a high-affinity and selective ligand for the dopamine transporter (DAT), a protein located on the presynaptic terminals of dopaminergic neurons. By binding to DAT, 18F-LBT-999 allows for the non-invasive visualization and quantification of dopaminergic innervation in the brain, particularly within the striatum. This imaging agent is primarily utilized in the clinical evaluation of Parkinson's disease and other parkinsonian syndromes to assess the loss of dopaminergic neurons, aiding in early diagnosis and the monitoring of disease progression. Its favorable kinetics and high signal-to-noise ratio make it a potent tool for neuroimaging research and clinical diagnostics.
- Brand names
- [18F] LBT-999
- Other names
- 8-((E)-4-fluorobut-2-enyl)-3beta-p-tolyl-8-azabicyclo[3.2.1]octane-2beta-carboxylic acid methyl esterFluorine-18 LBT-999Fluorine18 LBT-999Fluorine 18 LBT-999
02
Targets
DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on 18f-lbt-999.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18f-lbt-999.